N-acetiltransferase-2 gene polymorphisms and the susceptibility to prostate and thyroid cancers in Brazilian patients / Estudo das variantes alelicas da N-acetiltransferase 2 ( NAT2) em cancer de prostata e tireoide na população brasileira da região de Campinas

AUTOR(ES)
DATA DE PUBLICAÇÃO

2006

RESUMO

N-acetyltransferases (NAT), which are polymorphic in the population, metabolize important carcinogens such as different kinds of meat and tobacco products that have been directly implicated in the tumor initiation process. In order to investigate the role of NAT2 polymorphisms in the susceptibility to cancer in the Brazilian population from our region, we studied 6 polymorphisms (C282T; T481C; G590A; A803G; G857A; G191A) in differentiated thyroid cancer and 4 polymorphisms (T481C; G590A; A803G e G857A) in prostate cancer. We conducted a case-control prospective study comparing 126 prostate cancer to 101 benign prostatic hyperplasia patients paired for age, diet and environmental exposure; 139 thyroid cancer patients (112 papillary carcinomas and 27 follicular carcinomas) and 179 paired controls. Analyses were performed in DNA extracted from peripheral blood using the polymerase chain reaction-based restriction fragment length polymorphism method. We observed T481C (76.24%) and A803G (59.41%) polymorphisms with higher frequency among control patients than in prostate cancer cases (60.32% e 45.60%, p=0.0152 e 0.0186, respectively). On the contrary, G857A polymorphisms was more frequent among prostate cancer patients (18.4%) than in the benign hyperplasia control partients? group (5.94%; p=0.0044). Therefore, the presence of NAT2T481C polymorphism reduced the risk of prostate cancer (OR=2.115; 95% C.I=1.155-3.872). Likewise, the presence of NAT2A803G reduced the risk of prostate cancer (OR=1.973; 95%C.I=1.120-3.474; p=0.0186). On the contrary, the presence of G857A increased the risk for prostate cancer more than 4 times (OR=4.095; 95%C.I=1.551-10.812). The presence of a low acetylation phenotype increased the risk for prostate cancer more than 24 times (OR=24.145;95%CI=1.416-411.63). Regarding thyroid cancer, we observed that point mutations like A803G appears more frequently among thyroid carcinomas (46.76%) than in controls (31.84%) (p=0.0069), while G191A and C282T polymorphisms were more frequent among controls (25,70% and 68.16% of the cases, respectively) than among thyroid cancers (5,04% e 33,81%, respectively) (p=0,0001). Therefore, the inheritance of an A803G polymorphism represents an 1.8 times higher risk to thyroid cancer development (OR= 1.880; 95% IC= 1.189-2.973). On the other hand, the inheritance of G191A and C282T NAT2 polymorphisms represents a protection around 80,6% against the risk of thyroid cancer development (OR=0.153; 95% IC=0.067-0.352 and OR=0.239; 95% IC=0.149-0.382, respectively). In conclusion, our data demonstrate that NAT2 gene polymorphisms are associated to the risk to both prostate and thyroid cancer, suggesting they could become useful molecular markers of susceptibility to these tumors in our population

ASSUNTO(S)

heterociclicos metabolism aminas enzyme amines heterocyclic carcinogenos - metabolismo carcinogenic enzimas

ACESSO AO ARTIGO

Documentos Relacionados